We are bringing innovative medicines to cancer patients around the world

Oncologie is developing next-generation biologics and small molecules using cutting edge approaches to patient selection and clinical trial design. Our portfolio covers important targets in the tumor microenvironment. Our teams in Boston and Shanghai are working together to bring new therapies to patients.

We are bringing innovative medicines to cancer patients around the world

Oncologie is developing next-generation biologics and small molecules using cutting edge approaches to patient selection and clinical trial design. We have a portfolio that covers the spectrum of the cancer immunology landscape. Our teams in Boston and Shanghai are working together to bring new therapies to patients.

Bavituximab

Learn More

Bavituximab Overview

Bavituximab is an investigational monoclonal antibody that blocks activation of immunomodulatory TAM and TIM receptors on immune cells by phosphatidylserine (PS).

Lefitolimod

Learn More

Lefitolimod Overview

Lefitolimod is an investigational agonist of toll-like receptor 9 (TLR-9). It is a small, covalently closed DNA molecule that is taken up by immune cells and acts as an immune adjuvant in promoting an inflammatory tumor microenvironment.

Varisacumab

Learn More

Varisacumab Overview

Varisacumab is an investigational monoclonal antibody that binds to the vascular endothelial growth factor (VEGFA) and selectively inhibits the activation of VEGF receptor 2 (VEGFR-2).

 

This website uses cookies. By continuing to use this website you are giving consent to cookies being used. Click here to review our Privacy Policy.